生产企业：Nterica
NTR-101 is an investigational drug candidate developed by Nterica for alcohol-associated liver disease (ALD), targeting metabolic dysfunction, inflammation, and fibrosis.
NTR-101 is an investigational drug candidate developed by Nterica for alcohol-associated liver disease (ALD), targeting metabolic dysfunction, inflammation, and fibrosis.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
